SLC2A3 and Hypoglycemia: Recurrent moderate hypoglycemia is common in treated DM, and a study of streptozotocin-induced diabetic APP/PS1 mice indicated that recurrent hypoglycemia could promote AD via the damaged TRPC6/GLUT3 pathway [77].